Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 6/20 | 0.40 |
| ▸ | HRH1 | P35367 | 3/20 | 0.38 |
| ▸ | HTR6 | P50406 | 2/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | GRN | P28799 | 1/20 | 0.36 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.36 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.35 |
| ▸ | USP1 | O94782 | 3/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2811068 | 0.86 | TBXA2R (0.42) | TBXA2RHRH1HTR6MCHR1CNR1 | |
| SCHEMBL2809345 | 0.84 | TBXA2R (0.41) | TBXA2RHRH1HTR6MCHR1TBXAS1 | |
| SCHEMBL2814074 | 0.84 | TBXA2R (0.40) | TBXA2RHRH1HTR6MCHR1TBXAS1 | |
| SCHEMBL2816820 | 0.82 | TBXA2R (0.47) | TBXA2RHRH1HTR6CNR1CNR2 | |
| SCHEMBL951065 | 0.81 | TBXA2R (0.43) | TBXA2RHRH1HTR6MCHR1TBXAS1 | |
| SCHEMBL2813239 | 0.81 | TBXA2R (0.40) | TBXA2RHRH1HTR6MCHR1TBXAS1 | |
| SCHEMBL2815061 | 0.80 | TBXA2R (0.58) | TBXA2RHRH1CNR2TBXAS1 | |
| SCHEMBL2815715 | 0.80 | MCHR1 (0.49) | TBXA2RHRH1HTR6MCHR1CYP2D6 | |
| SCHEMBL2813886 | 0.78 | TBXA2R (0.41) | TBXA2RHRH1HTR6MCHR1TBXAS1 | |
| SCHEMBL2812789 | 0.78 | HRH1 (0.48) | TBXA2RHRH1HTR6TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9625475-B2 | Indole and indoline derivatives and methods of use thereof | ABBVIE INC. (US) | 2017-04-18 | — | — | US | claimed |
| US-20100249105-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-09-30 | — | — | US | claimed |
| US-9983218-B2 | Indole and indoline derivatives and methods of use thereof | ABBVIE INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-20180024144-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | ABBVIE INC. (US) | 2018-01-25 | — | — | US | disclosed |
| US-9625475-B2 | Indole and indoline derivatives and methods of use thereof | ABBVIE INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-20100249105-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249105-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | IDO1, IDO2, TPH1 | TBXA2R 419/4885HRH1 457/4885HTR6 21/4885 |
| US-20180024144-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | IDO1, IDO2, TPH1 | TBXA2R 419/4885HRH1 457/4885HTR6 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.